• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pyxis Oncology, Inc. - Common Stock (NQ:PYXS)

1.540 +0.010 (+0.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pyxis Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
February 03, 2026
From Pyxis Oncology
Via GlobeNewswire
News headline image
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
January 12, 2026
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
January 09, 2026
Via Chartmill
News headline image
Unusual volume stocks in Tuesday's session ↗
December 23, 2025
Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session. 
Via Chartmill
News headline image
Top movers in Thursday's session ↗
December 18, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
December 18, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
December 18, 2025
In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Discover the top movers in Thursday's pre-market session. ↗
December 18, 2025
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
December 18, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in Upcoming Investor Conferences
November 03, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
November 03, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
October 13, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
October 09, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
October 06, 2025
 
Via Benzinga
News headline image
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in September Investor and Industry Conferences
August 21, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
May 14, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
April 25, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
April 02, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
March 25, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 18, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
March 03, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
February 26, 2025
Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with... 
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
February 04, 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move ↗
December 20, 2024
Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource allocation and challenges. 
Via Benzinga
News headline image
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
December 19, 2024
From Pyxis Oncology
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
November 21, 2024
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap